MicroRNAs as prognostic biomarkers for (cancer–associated) venous thromboembolism

Anijs, Rayna J.S.; Nguyen, Yen Nhi; Cannegieter, Suzanne C.; Versteeg, Henri H.; Buijs, Jeroen T.

doi:10.1016/j.jtha.2022.09.001

Cited by 15 publications

(4 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its potential aim is mRNA in genes VEGF and eNOS. Unfortunately most of the studies used only small sample sizes and lacked external validation (12).…”

Section: Discussionmentioning

confidence: 99%

Platelet miRNA Expression in Patients with Sticky Platelet Syndrome

Belakova,

Zolkova,

Vadelova

et al. 2023

Acta Medica Martiniana

View full text Add to dashboard Cite

Sticky platelet syndrome (SPS) is a disorder with familial occurrence and autosomal dominant trait characterized by platelet hyperaggregability in response to a low concentration of adenosine diphosphate (ADP) and/or epinephrine (EPI). The etiology of SPS may be associated with platelet microRNAs (miRNAs), which are considered as potential biomarkers of platelet function and antiplatelet therapy. We were monitoring the expression of platelet miRNAs in patients with laboratory diagnosed SPS and healthy controls. We have found a statistically significant increased expression of both miR-423-5p and miR-338-3p as well as a statistically significant decreased expression of miR-425-5p between the group of patients with diagnosed SPS type II and the group of healthy controls, which seems to be an interesting issue for a further research.

show abstract

“…Its potential aim is mRNA in genes VEGF and eNOS. Unfortunately most of the studies used only small sample sizes and lacked external validation (12).…”

Section: Discussionmentioning

confidence: 99%

Platelet miRNA Expression in Patients with Sticky Platelet Syndrome

Belakova,

Zolkova,

Vadelova

et al. 2023

Acta Medica Martiniana

View full text Add to dashboard Cite

show abstract

“…Table 2 presents the relevant studies presenting modalities and importance of VTE screening among ambulatory cancer patients. microRNAs (miRNAs) represent a promising class of biomarkers in VTE prediction in cancer, but until now, only a few small-sample-size studies, lacking external validation, have investigated their role in this setting [29]. The long non-coding RNAs (lncRNAs) may have a role as well in VTE pathogenesis [30].…”

Section: Vte Screening In Ambulatory High-risk Oncologic Patientsmentioning

confidence: 99%

Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice

Drăgan,

Drăgan

2024

Cancers

View full text Add to dashboard Cite

Many cancer patients will experience venous thromboembolism (VTE) at some stage, with the highest rate in the initial period following diagnosis. Novel cancer therapies may further enhance the risk. VTE in a cancer setting is associated with poor prognostic, a decreased quality of life, and high healthcare costs. If thromboprophylaxis in hospitalized cancer patients and perioperative settings is widely accepted in clinical practice and supported by the guidelines, it is not the same situation in ambulatory cancer patient settings. The guidelines do not recommend primary thromboprophylaxis, except in high-risk cases. However, nowadays, risk stratification is still challenging, although many tools have been developed. The Khrorana score remains the most used method, but it has many limits. This narrative review aims to present the current relevant knowledge of VTE risk assessment in ambulatory cancer patients, starting from the guideline recommendations and continuing with the specific risk assessment methods and machine learning models approaches. Biomarkers, genetic, and clinical features were tested alone or in groups. Old and new models used in VTE risk assessment are exposed, underlining their clinical utility. Imaging and biomolecular approaches to VTE screening of outpatients with cancer are also presented, which could help clinical decisions.

show abstract

“…Among the several factors contributing to this disappointing behavior, the absence of valuable clinical tools able to evaluate the specific and individualized risk of venous thromboembolism may play a major role. Accordingly, the authors of the recently published European Society of Medical Oncology Guidelines [17] strongly endorsed the development of cancer-specific risk assessment models to further refine current risk stratification approaches or to develop new models that incorporate promising biomarkers [22][23][24], given that thrombogenic potential varies depending on the type of cancer, the setting of disease, or the presence of certain oncogene mutations/rearrangements [25][26][27][28][29][30].…”

Section: Introductionmentioning

confidence: 99%

Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention

Falanga,

Lorusso,

Colombo

et al. 2024

Cancers

View full text Add to dashboard Cite

The prevention and appropriate management of venous thromboembolism in cancer patients is of paramount importance. However, the literature data report an underestimation of this major problem in patients with gynecological cancers, with an inconsistent venous thromboembolism risk assessment and prophylaxis in this patient setting. This narrative review provides a comprehensive overview of the available evidence regarding the management of venous thromboembolism in cancer patients, focusing on the specific context of gynecological tumors, exploring the literature discussing risk factors, risk assessment, and pharmacological prophylaxis. We found that the current understanding and management of venous thromboembolism in gynecological malignancy is largely based on studies on solid cancers in general. Hence, further, larger, and well-designed research in this area is needed.

show abstract

MicroRNAs as prognostic biomarkers for (cancer–associated) venous thromboembolism

Cited by 15 publications

References 65 publications

Platelet miRNA Expression in Patients with Sticky Platelet Syndrome

Platelet miRNA Expression in Patients with Sticky Platelet Syndrome

Novel Insights in Venous Thromboembolism Risk Assessment Methods in Ambulatory Cancer Patients: From the Guidelines to Clinical Practice

Gynecological Cancer and Venous Thromboembolism: A Narrative Review to Increase Awareness and Improve Risk Assessment and Prevention

Contact Info

Product

Resources

About